| Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR CE Wainwright, JS Elborn, BW Ramsey, G Marigowda, X Huang, M Cipolli, ... New England Journal of Medicine 373 (3), 220-231, 2015 | 1648 | 2015 |
| Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis HF Weisman, T Bartow, MK Leppo, HC Marsh Jr, GR Carson, MF Concino, ... Science 249 (4965), 146-151, 1990 | 1251 | 1990 |
| Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation FJ Accurso, SM Rowe, JP Clancy, MP Boyle, JM Dunitz, PR Durie, ... New England Journal of Medicine 363 (21), 1991-2003, 2010 | 945 | 2010 |
| Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health PA Flume, BP O'Sullivan, KA Robinson, CH Goss, PJ Mogayzel Jr, ... American journal of respiratory and critical care medicine 176 (10), 957-969, 2007 | 831 | 2007 |
| Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation JP Clancy, SM Rowe, FJ Accurso, ML Aitken, RS Amin, MA Ashlock, ... Thorax 67 (1), 12-18, 2012 | 666 | 2012 |
| Guide to bone health and disease in cystic fibrosis RM Aris, PA Merkel, LK Bachrach, DS Borowitz, MP Boyle, SL Elkin, ... The Journal of Clinical Endocrinology & Metabolism 90 (3), 1888-1896, 2005 | 577 | 2005 |
| A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised … MP Boyle, SC Bell, MW Konstan, SA McColley, SM Rowe, E Rietschel, ... The lancet Respiratory medicine 2 (7), 527-538, 2014 | 545 | 2014 |
| Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier BC Tang, M Dawson, SK Lai, YY Wang, JS Suk, M Yang, P Zeitlin, ... Proceedings of the National Academy of Sciences 106 (46), 19268-19273, 2009 | 542 | 2009 |
| International committee on mental health in cystic fibrosis: cystic fibrosis foundation and European cystic fibrosis society consensus statements for screening and treating … AL Quittner, J Abbott, AM Georgiopoulos, L Goldbeck, B Smith, ... Thorax 71 (1), 26-34, 2016 | 414 | 2016 |
| Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis EC Dasenbrook, W Checkley, CA Merlo, MW Konstan, N Lechtzin, ... Jama 303 (23), 2386-2392, 2010 | 412 | 2010 |
| The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles JS Suk, SK Lai, YY Wang, LM Ensign, PL Zeitlin, MP Boyle, J Hanes Biomaterials 30 (13), 2591-2597, 2009 | 376 | 2009 |
| Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis EC Dasenbrook, CA Merlo, M Diener-West, N Lechtzin, MP Boyle American journal of respiratory and critical care medicine 178 (8), 814-821, 2008 | 368 | 2008 |
| A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect MP Boyle, K De Boeck The Lancet Respiratory Medicine 1 (2), 158-163, 2013 | 339 | 2013 |
| Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax PA Flume, PJ Mogayzel Jr, KA Robinson, RL Rosenblatt, L Quittell, ... American journal of respiratory and critical care medicine 182 (3), 298-306, 2010 | 337 | 2010 |
| Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation CS Schneider, Q Xu, NJ Boylan, J Chisholm, BC Tang, BS Schuster, ... Science advances 3 (4), e1601556, 2017 | 293 | 2017 |
| Longitudinal association between medication adherence and lung health in people with cystic fibrosis MN Eakin, A Bilderback, MP Boyle, PJ Mogayzel, KA Riekert Journal of Cystic Fibrosis 10 (4), 258-264, 2011 | 290 | 2011 |
| CFTR modulator theratyping: Current status, gaps and future directions JP Clancy, CU Cotton, SH Donaldson, GM Solomon, DR VanDevanter, ... Journal of Cystic Fibrosis 18 (1), 22-34, 2019 | 288 | 2019 |
| The association between depression, lung function, and health-related quality of life among adults with cystic fibrosis KA Riekert, SJ Bartlett, MP Boyle, JA Krishnan, CS Rand Chest 132 (1), 231-237, 2007 | 260 | 2007 |
| Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate PL Zeitlin, M Diener-West, RC Rubenstein, MP Boyle, CKK Lee, ... Molecular Therapy 6 (1), 119-126, 2002 | 259 | 2002 |
| Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy P Mastorakos, AL Da Silva, J Chisholm, E Song, WK Choi, MP Boyle, ... Proceedings of the National Academy of Sciences 112 (28), 8720-8725, 2015 | 223 | 2015 |
